Xelyanz ( tofacitinib ) 5 мг 60 таб Cipla, India
Indication
Rheumatoid arthritis
Tofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have had an inadequate response to or are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). drugs Tofacitinib can be prescribed as monotherapy in case of intolerance to MTX or inappropriateness of MTX treatment (see sections "Particulars of use" and "Interaction with other drugs and other types of interactions").
Psoriatic arthritis
Tofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response to, or are intolerant to, prior disease-modifying antirheumatic drug (DMARD) therapy.
Ankylosing spondylitis
Tofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have not responded adequately to standard therapy.
Ulcerative colitis
Tofacitinib is indicated for the treatment of adult patients with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to, loss of response to, or intolerance to standard therapy or biologic therapy.
Juvenile idiopathic arthritis (JIA)
Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor-positive [RF+] or [RF-] polyarthritis and advanced oligoarthritis) in pediatric patients weighing ≥ 40 kg who have had an inadequate response to prior DMARD therapy
Tofacitinib can be used in combination with MTX or as monotherapy in case of intolerance to MTX or if continued use of MTX is not appropriate.
-
Commercial name:Ксельянз
-
Сhemical name:Тофацитиниб
-
Dosage:5 mg
-
Quantity:60
-
Release form:Таю
-
Производитель:Сірla, Индия